Single dose of Profectus' Ebola vaccine works in monkeys
This article was originally published in Scrip
Executive Summary
A single dose of Profectus BioSciences' experimental Ebola vaccine, which uses the firm's VesiculoVax vector platform, provided rapid and complete protection from sickness and death in macaques when challenged with a lethal dose of the Makona form of the Zaire virus – the strain responsible for the ongoing epidemic in West Africa, which has infected more than 25,500 people, killing over 10,500.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.